Literature DB >> 20432394

Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality.

Benjamin Williams1, Madhav Menon, Daniel Satran, Daniel Hayward, James S Hodges, M Nicholas Burke, Randall K Johnson, Anil K Poulose, Jay H Traverse, Timothy D Henry.   

Abstract

OBJECTIVES: To determine the contemporary prevalence of and mortality in patients with coronary artery disease (CAD) not amenable to revascularization.
BACKGROUND: A growing number of patients have severe CAD with ongoing angina despite optimal medical therapy which is not amenable to traditional revascularization. Limited data exist on contemporary prevalence and outcome for these patients.
METHODS: Clinical and angiographic data were reviewed for 493 consecutive patients undergoing coronary angiography and revascularization if indicated. Patients were categorized into six groups: (1) normal coronary arteries, (2) CAD <70%, (3) CAD >70% with complete revascularization by percutaneous intervention or coronary artery bypass grafting, (4) CAD >70% with partial revascularization, (5) CAD >70% treated medically, and (6) CAD >70% on optimal medical therapy with no revascularization option. All-cause mortality at 3 years was determined.
RESULTS: Prevalence for groups 1-6 was 14.8, 19.5, 36.9, 12.8, 9.3, and 6.7%, respectively. Three-year mortality increased with angiographic severity of CAD: 2.7, 6.3, 8.2, 12.7, 17.4, and 15.2%, respectively. Patients with incomplete revascularization (groups 4-6, n = 142) had higher mortality than completely revascularized patients (groups 1-3, n = 351): 14.8 vs. 6.6% (P = 0.004).
CONCLUSIONS: In a contemporary series of patients undergoing coronary angiography, 28.8% (142/493) of patients had significant CAD and did not undergo complete revascularization, including 12.8% partially revascularized, 9.3% managed medically, and 6.7% with "no-option." These patients had higher mortality at 3 years (14.8 vs. 6.6%, P = 0.004) when compared with completely revascularized patients. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20432394     DOI: 10.1002/ccd.22431

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  28 in total

1.  Pacing to reduce refractory angina in patients with severe coronary artery disease: a crossover pilot trial.

Authors:  Craig M Stolen; Yui-Ming Lam; Chung-Wah Siu; Chu-Pak Lau; J Anthony Parker; Thomas H Hauser; Hung-Fat Tse
Journal:  J Cardiovasc Transl Res       Date:  2011-10-26       Impact factor: 4.132

Review 2.  Management of Refractory Angina Pectoris.

Authors:  Kevin Cheng; Paul Sainsbury; Michael Fisher; Ranil de Silva
Journal:  Eur Cardiol       Date:  2016-12

3.  Cardiovascular risk factors cause premature rarefaction of the collateral circulation and greater ischemic tissue injury.

Authors:  Scott M Moore; Hua Zhang; Nobuyo Maeda; Claire M Doerschuk; James E Faber
Journal:  Angiogenesis       Date:  2015-04-11       Impact factor: 9.596

4.  Echocardiographic evaluation of the effects of stem cell therapy on perfusion and function in ischemic cardiomyopathy.

Authors:  Yoichi Inaba; Brian P Davidson; Sajeevani Kim; Ya Ni Liu; William Packwood; J Todd Belcik; Aris Xie; Jonathan R Lindner
Journal:  J Am Soc Echocardiogr       Date:  2013-12-04       Impact factor: 5.251

5.  Safety and efficacy of extracorporeal shock wave myocardial revascularization therapy for refractory angina pectoris.

Authors:  Andrew Cassar; Megha Prasad; Martin Rodriguez-Porcel; Guy S Reeder; Darshak Karia; Anthony N DeMaria; Amir Lerman
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

6.  A prospective study of patients with refractory angina: outcomes and the role of high-sensitivity troponin T.

Authors:  Nilson T Poppi; Luís H W Gowdak; Luciana O C Dourado; Eduardo L Adam; Thiago N P Leite; Bruno M Mioto; José E Krieger; Luiz A M César; Alexandre C Pereira
Journal:  Clin Cardiol       Date:  2016-10-18       Impact factor: 2.882

Review 7.  Treatment of refractory angina in patients not suitable for revascularization.

Authors:  Timothy D Henry; Daniel Satran; E Marc Jolicoeur
Journal:  Nat Rev Cardiol       Date:  2013-12-24       Impact factor: 32.419

8.  A Novel Intra-aortic Device Designed for Coronary Blood Flow Amplification in Unrevascularizable Patients.

Authors:  Udi Nussinovitch; Giorgi Shtenberg; Ariel Roguin; Yair Feld
Journal:  J Cardiovasc Transl Res       Date:  2016-06-03       Impact factor: 4.132

9.  Long-term outcomes of patients with multivessel coronary artery disease presenting non-ST-segment elevation acute coronary syndromes.

Authors:  Piotr Desperak; Michał Hawranek; Paweł Gąsior; Aneta Desperak; Andrzej Lekston; Mariusz Gąsior
Journal:  Cardiol J       Date:  2017-10-05       Impact factor: 2.737

Review 10.  Current State of Stem Cell Therapy for Ischemic Heart Disease.

Authors:  Thomas J Povsic
Journal:  Curr Cardiol Rep       Date:  2016-02       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.